{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:44:59Z","timestamp":1790232299112,"version":"4.1.0"},"reference-count":35,"publisher":"Bioscientifica","issue":"7","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"abstract":"<jats:p>\n                    The objective of the study was to evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH&amp;PRL-Pit-NET) compared to their efficacy in patients with acromegaly caused by a GH-secreting pituitary neuroendocrine tumor (GH-Pit-NET). This is a multicenter retrospective study of patients with acromegaly on treatment with pasireotide and\/or pegvisomant. Patients were classified in two groups: GH&amp;PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were &gt;200 ng\/dL regardless of the PRL-IHC and GH-Pit-NETs when the previously mentioned criteria were not met. A total of 28 cases with GH&amp;PRL-Pit-NETs and 122 with GH-Pit-NETs met the inclusion criteria. GH&amp;PRL-Pit-NETs presented at a younger age, caused hypopituitarism, and were invasive more frequently than GH-Pit-NETs. There were 124 patients treated with pegvisomant and 49 with pasireotide at any time. The efficacy of pegvisomant for IGF-1 normalization was of 81.5% and of pasireotide of 71.4%. No differences in IGF-1 control with pasireotide and with pegvisomant were observed between GH&amp;PRL-Pit-NETs and GH-Pit-NETs\n                    <jats:italic>.<\/jats:italic>\n                    All GH&amp;PRL-Pit-NET cases treated with pasireotide (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096) and 82.6% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919\/23) of the cases treated with pegvisomant normalized PRL levels. No differences in the rate of IGF-1 control between pegvisomant and pasireotide were detected in patients with GH&amp;PRL-Pit-NETs (84.9% vs 66.7%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.178). We conclude that despite the more aggressive behavior of GH&amp;PRL-Pit-NETs than GH-Pit-NETs, no differences in the rate of IGF-1 control with pegvisomant and pasireotide were observed between both groups, and both drugs have shown to be effective treatments to control IGF-1 and PRL hypersecretion in these tumors.\n                  <\/jats:p>","DOI":"10.1530\/erc-24-0043","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T11:05:53Z","timestamp":1715079953000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":8,"title":["Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs"],"prefix":"10.1530","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":true,"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain & Instituto de Investigaci\u00f3n Biom\u00e9dica Ram\u00f3n y Cajal (IRYCIS), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Vall de Hebr\u00f3n, CIBERER U747 (ISCIII), ENDO-ERN, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelmiro","family":"Men\u00e9ndez Torre","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias & Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ir\u00eda","family":"Novoa-Testa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario de A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cordido","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario de A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider","family":"Pascual-Corrales","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain & Instituto de Investigaci\u00f3n Biom\u00e9dica Ram\u00f3n y Cajal (IRYCIS), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Rodr\u00edguez Berrocal","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Guerrero-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario de Bellvitge, Catalu\u00f1a L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Vicente","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario de Toledo, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Percovich Hualpa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Garc\u00eda-Centeno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Ollero Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Irigaray Echarri","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Moure Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department Endocrinology and Nutrition, Hospital Universitario de Cruces, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Novo-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-7289","authenticated-orcid":true,"given":"Mar\u00eda","family":"Calatayud","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Doce de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Villar-Taibo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario de Santiago de Compostela, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Bernab\u00e9u","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario de Santiago de Compostela, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4448-7941","authenticated-orcid":true,"given":"Cristina","family":"Alvarez-Escola","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ben\u00edtez Valderrama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Tenorio-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Abell\u00e1n Galiana","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital General Universitario de Castell\u00f3n, Castell\u00f3n, Spain"},{"name":"Department of Medicine and Surgery, Universidad Cardenal Herrera-CEU, CEU Universities, Castell\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Venegas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Gonz\u00e1lez-Molero","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Regional Universitario de M\u00e1laga, IBIMA Plataforma Bionand, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1985","authenticated-orcid":true,"given":"Pedro","family":"Iglesias","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Blanco-Carrera","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Pr\u00edncipe de Asturias, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Vidal-Ostos De Lara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Pr\u00edncipe de Asturias, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"de Miguel Novoa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"L\u00f3pez Mezquita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Alexandra","family":"Hanzu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iban","family":"Aldecoa","sequence":"additional","affiliation":[{"name":"Biomedical Diagnostic Center, Department of Pathology, Hospital Clinic - University of Barcelona, Barcelona, Spain"},{"name":"Neurological Tissue Bank of the Biobank, FCRB-IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Aznar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario De Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-9508","authenticated-orcid":true,"given":"Cristina","family":"Lamas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario De Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aulinas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, IR-SANT PAU, CIBERER U747 (ISCIII), Barcelona, Spain"},{"name":"Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queralt","family":"Asla","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, IR-SANT PAU, CIBERER U747 (ISCIII), Barcelona, Spain"},{"name":"Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gracia Gimeno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Royo Villanova, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Recio-C\u00f3rdova","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Royo Villanova, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Avil\u00e9s-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Cl\u00ednico San Cecilio, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Asensio-Wandosell","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias i Pujol, Catalu\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-4046","authenticated-orcid":true,"given":"Miguel","family":"Sampedro-N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario La Princesa Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"C\u00e1mara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Paja Fano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, OSI Bilbao-Basurto, Hospital Universitario de Basurto & University of the Basque Country UPV\/EHU, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ruz-Caracuel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS & CIBER C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fajardo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario La Ribera, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario La Princesa Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-7195","authenticated-orcid":true,"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias i Pujol, Catalu\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Journal of Clinical Medicine","article-title":"The clinicopathological spectrum of acromegaly","volume":"8","author":"Akirov","year":"2019","unstructured":"Akirov AAsa SLAmer LShimon I & Ezzat S2019The clinicopathological spectrum of acromegaly. Journal of Clinical Medicine8. (https:\/\/doi.org\/10.3390\/JCM8111962)"},{"key":"bib3","series-title":"International Journal of Molecular Sciences","first-page":"14002","article-title":"Prolactin and growth hormone signaling and interlink focused on the mammosomatotroph paradigm: a comprehensive review of the literature","volume":"24","author":"Araujo-Castro","year":"2023","unstructured":"Araujo-Castro M , Marazuela MPuig-Domingo M & Biagetti B2023Prolactin and growth hormone signaling and interlink focused on the mammosomatotroph paradigm: a comprehensive review of the literature. International Journal of Molecular Sciences2414002. (https:\/\/doi.org\/10.3390\/IJMS241814002)"},{"key":"bib2","series-title":"Journal of Clinical Endocrinology and Metabolism","article-title":"Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas: a series of 604 cases","author":"Araujo-Castro","year":"2024","unstructured":"Araujo-Castro MBiagetti BTorre MENovoa-Testa ICordido FCorrales PEBerrocal VRGuerrero-P\u00e9rez FVicente APercovich JC, et al.2024Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas: a series of 604 cases. Journal of Clinical Endocrinology and Metabolism. (https:\/\/doi.org\/10.1210\/clinem\/dgae126)"},{"key":"bib4","series-title":"Frontiers in Endocrinology","first-page":"984877","article-title":"Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain","volume":"13","author":"Biagetti","year":"2022","unstructured":"Biagetti BIglesias PVillar-Taibo RMoure MDPaja MAraujo-Castro MAres J\u00c1lvarez-Escola CVicente A\u00c1lvarez Guivernau \u00c8, et al.2022Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain. Frontiers in Endocrinology13984877. (https:\/\/doi.org\/10.3389\/FENDO.2022.984877)"},{"key":"bib5","series-title":"Journal of Clinical Medicine","article-title":"Genetics of acromegaly and gigantism","volume":"10","author":"Bogus\u0142awska","year":"2021","unstructured":"Bogus\u0142awska A & Korbonits M2021Genetics of acromegaly and gigantism. Journal of Clinical Medicine10. (https:\/\/doi.org\/10.3390\/JCM10071377)."},{"key":"bib6","series-title":"European Journal of Endocrinology","first-page":"419","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","unstructured":"Buchfelder Mvan der Lely AJBiller BMKWebb SMBrue TStrasburger CJGhigo ECamacho-Hubner CPan KLavenberg J, et al.2018Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. European Journal of Endocrinology179419\u2013427. (https:\/\/doi.org\/10.1530\/EJE-18-0616)"},{"key":"bib7","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1825","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","unstructured":"Carmichael JDBonert VSNu\u00f1o MLy D & Melmed S2014Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. Journal of Clinical Endocrinology and Metabolism991825\u20131833. (https:\/\/doi.org\/10.1210\/JC.2013-3757)"},{"key":"bib8","series-title":"European Journal of Endocrinology","first-page":"217","article-title":"Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","unstructured":"Chiloiro SGiampietro AMirra FDonfrancesco FTartaglione TMattogno PPAngelini FLiverana LGessi MCarmelo A, et al.2021Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. European Journal of Endocrinology184217\u2013229. (https:\/\/doi.org\/10.1530\/EJE-20-0767)"},{"key":"bib9","series-title":"Endocrine Reviews","first-page":"247","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","unstructured":"Colao AAuriemma RSLombardi G & Pivonello R2011Resistance to somatostatin analogs in acromegaly. Endocrine Reviews32247\u2013271. (https:\/\/doi.org\/10.1210\/er.2010-0002)"},{"key":"bib10","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"791","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","unstructured":"Colao ABronstein MDFreda PGu FShen CCGadelha MFleseriu Mvan der Lely AJFarrall AJHermosillo Res\u00e9ndiz K, et al.2014Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism99791\u2013799. (https:\/\/doi.org\/10.1210\/JC.2013-2480)"},{"key":"bib11","series-title":"European Journal of Endocrinology","first-page":"595","article-title":"T2-signal intensity, sstr expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","unstructured":"Coopmans ECSchneiders JJEl-Sayed NErler NSHofland LJvan der Lely AJPetrossians PPotorac JMuhammad A & Neggers SJCMM2020T2-signal intensity, sstr expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. European Journal of Endocrinology182595\u2013605. (https:\/\/doi.org\/10.1530\/EJE-19-0840)"},{"key":"bib12","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2892","article-title":"Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies","volume":"104","author":"Feola","year":"2019","unstructured":"Feola TCozzolino ASimonelli ISbardella EPozza CGiannetta EGianfrilli DPasqualetti PLenzi A & Isidori AM2019Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. Journal of Clinical Endocrinology and Metabolism1042892\u20132902. (https:\/\/doi.org\/10.1210\/JC.2018-02281)"},{"key":"bib13","series-title":"Pituitary","first-page":"1","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","unstructured":"Fleseriu MBiller BMKFreda PUGadelha MRGiustina AKatznelson LMolitch MESamson SLStrasburger CJvan der Lely AJ, et al.2021A Pituitary Society update to acromegaly management guidelines. Pituitary241\u201313. (https:\/\/doi.org\/10.1007\/s11102-020-01091-7)"},{"key":"bib14","series-title":"European Journal of Endocrinology","first-page":"525","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","unstructured":"Fleseriu MF\u00fchrer-Sakel Dvan der Lely AJDe Marinis LBrue Tvan der Lans-Bussemaker JHey-Hadavi JCamacho-Hubner CWajnrajch MPValluri SR, et al.2021More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. European Journal of Endocrinology185525\u2013538. (https:\/\/doi.org\/10.1530\/EJE-21-0239)"},{"key":"bib15","series-title":"Endocrine","first-page":"206","article-title":"Combined treatment of somatostatin analogues with pegvisomant in acromegaly","volume":"52","author":"Franck","year":"2016","unstructured":"Franck SEMuhammad Avan der Lely AJ & Neggers SJCMM2016Combined treatment of somatostatin analogues with pegvisomant in acromegaly. Endocrine52206\u2013213. (https:\/\/doi.org\/10.1007\/S12020-015-0810-8)"},{"key":"bib17","series-title":"Lancet. Diabetes and Endocrinology","first-page":"875","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","unstructured":"Gadelha MRBronstein MDBrue TCoculescu MFleseriu MGuitelman MPronin VRaverot GShimon IKodama Lievre KK, et al.2014Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet. Diabetes and Endocrinology2875\u2013884. (https:\/\/doi.org\/10.1016\/S2213-8587(1470169-X)"},{"key":"bib16","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"e1571","article-title":"Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience","volume":"108","author":"Gadelha","year":"2023","unstructured":"Gadelha MVer\u00f4nica Marques NVFialho CScaf CLamback EAntunes XSantos EMagalh\u00e3es J & Wildemberg LE2023Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience. Journal of Clinical Endocrinology and Metabolism108e1571\u2013e1579. (https:\/\/doi.org\/10.1210\/CLINEM\/DGAD378)"},{"key":"bib19","series-title":"Nature Reviews. Endocrinology","first-page":"243","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","unstructured":"Giustina AChanson PKleinberg DBronstein MDClemmons DRKlibanski Avan der Lely AJStrasburger CJLamberts SWHo KKY, et al.2014Expert consensus document: a consensus on the medical treatment of acromegaly. Nature Reviews. Endocrinology10243\u2013248. (https:\/\/doi.org\/10.1038\/nrendo.2014.21)"},{"key":"bib18","series-title":"Pituitary","first-page":"7","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","unstructured":"Giustina ABiermasz NCasanueva FFFleseriu MMortini PStrasburger Cvan der Lely AJWass JMelmed S & Acromegaly Consensus Group2024Consensus on criteria for acromegaly diagnosis and remission. Pituitary277\u201322. (https:\/\/doi.org\/10.1007\/S11102-023-01360-1)"},{"key":"bib20","series-title":"Frontiers in Endocrinology","first-page":"807054","article-title":"Hyperprolactinemia and hypopituitarism in acromegaly and effect of pituitary surgery: long-term follow-up on 529 patients","volume":"12","author":"Guo","year":"2021","unstructured":"Guo XZhang RZhang DWang ZGao LYao YDeng KBao XFeng MXu Z, et al.2021Hyperprolactinemia and hypopituitarism in acromegaly and effect of pituitary surgery: long-term follow-up on 529 patients. Frontiers in Endocrinology12807054. (https:\/\/doi.org\/10.3389\/fendo.2021.807054)"},{"key":"bib21","series-title":"Archives of Medical Research","first-page":"102884","article-title":"Efficacy and safety of pegvisomant in the treatment of acromegaly","volume":"54","author":"Haberbosch","year":"2023","unstructured":"Haberbosch L & Strasburger CJ2023Efficacy and safety of pegvisomant in the treatment of acromegaly. Archives of Medical Research54102884. (https:\/\/doi.org\/10.1016\/J.ARCMED.2023.102884)"},{"key":"bib22","series-title":"Clinical Endocrinology","first-page":"72","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","unstructured":"Heck ARingstad GFougner SLCasar-Borota ONome TRamm-Pettersen J & Bollerslev J2012Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology7772\u201378. (https:\/\/doi.org\/10.1111\/J.1365-2265.2011.04286.X)"},{"key":"bib23","series-title":"Lancet. Diabetes and Endocrinology","first-page":"209","article-title":"A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis","volume":"12","author":"Ho","year":"2024","unstructured":"Ho KKYFleseriu MWass JKatznelson LRaverot GLittle ASCasta\u00f1o JPReincke MLopes MBKaiser UB, et al.2024A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis. Lancet. Diabetes and Endocrinology12209\u2013214. (https:\/\/doi.org\/10.1016\/S2213-8587(2300382-0)"},{"key":"bib24","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3933","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","unstructured":"Katznelson LLaws ERJrMelmed SMolitch MEHassan Murad MHUtz AWass JAH & Endocrine Society2014Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism993933\u20133951. (https:\/\/doi.org\/10.1210\/jc.2014-2700)"},{"key":"bib25","series-title":"Endocrine","first-page":"310","article-title":"Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up","volume":"66","author":"Lv","year":"2019","unstructured":"Lv LJiang YYin SHu YChen CMa WJiang S & Zhou P2019Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up. Endocrine66310\u2013318. (https:\/\/doi.org\/10.1007\/s12020-019-02029-1)"},{"key":"bib26","series-title":"Archives of Medical Research","first-page":"102924","article-title":"Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly","volume":"54","author":"Marques-Pamies","year":"2023","unstructured":"Marques-Pamies M , Gil JJord\u00e0 M & Puig-Domingo M2023Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly. Archives of Medical Research54102924. (https:\/\/doi.org\/10.1016\/J.ARCMED.2023.102924)"},{"key":"bib27","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"915","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","unstructured":"Muhammad ACoopmans ECGatto FFranck SEJanssen JAMJLvan der Lely AJHofland LJ & Neggers SJCMM2019Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. Journal of Clinical Endocrinology and Metabolism104915\u2013924. (https:\/\/doi.org\/10.1210\/JC.2018-01524)"},{"key":"bib28","series-title":"Endocrine Pathology","first-page":"82","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","unstructured":"Obari ASano TOhyama KKudo ERong Qian ZRYoneda ARayhan NMustafizur Rahman M & Yamada S2008Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocrine Pathology1982\u201391. (https:\/\/doi.org\/10.1007\/S12022-008-9029-Z)"},{"key":"bib29","series-title":"Nature Reviews. Endocrinology","first-page":"722","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","unstructured":"Petersenn SFleseriu MCasanueva FFGiustina ABiermasz NBiller BMKBronstein MChanson PFukuoka HGadelha M, et al.2023Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nature Reviews. Endocrinology19722\u2013740. (https:\/\/doi.org\/10.1038\/S41574-023-00886-5)"},{"key":"bib30","series-title":"Frontiers in Endocrinology","first-page":"648411","article-title":"Pasireotide in the personalized treatment of acromegaly","volume":"12","author":"Puig-Domingo","year":"2021","unstructured":"Puig-Domingo MBernab\u00e9u IPic\u00f3 ABiagetti BGil JAlvarez-Escol\u00e1 CJord\u00e0 MMarques-Pamies MSoldevila BG\u00e1lvez MA, et al.2021Pasireotide in the personalized treatment of acromegaly. Frontiers in Endocrinology12648411. (https:\/\/doi.org\/10.3389\/FENDO.2021.648411)"},{"key":"bib31","series-title":"Journal of Endocrinological Investigation","first-page":"575","article-title":"How to improve effectiveness of pegvisomant treatment in acromegalic patients","volume":"41","author":"Ragonese","year":"2018","unstructured":"Ragonese MGrottoli SMaffei PAlibrandi AAmbrosio MRArnaldi GBianchi APuglisi SZatelli MCDe Marinis L, et al.2018How to improve effectiveness of pegvisomant treatment in acromegalic patients. Journal of Endocrinological Investigation41575\u2013581. (https:\/\/doi.org\/10.1007\/S40618-017-0773-0)"},{"key":"bib32","series-title":"Journal of Neurosurgery","first-page":"147","article-title":"Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes","volume":"131","author":"Rick","year":"2018","unstructured":"Rick JJahangiri AFlanigan PMChandra AKunwar SBlevins L & Aghi MK2018Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. Journal of Neurosurgery131147\u2013153. (https:\/\/doi.org\/10.3171\/2018.4.JNS18230)"},{"key":"bib33","series-title":"Clinical Endocrinology","first-page":"378","article-title":"Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly","volume":"99","author":"Ruiz","year":"2023","unstructured":"Ruiz SGil JBiagetti BVenegas EC\u00e1mara RGarcia-Centeno RG\u00e1lvez M\u00c1Pic\u00f3 AMaraver SGonz\u00e1lez I, et al.2023Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clinical Endocrinology99378\u2013385. (https:\/\/doi.org\/10.1111\/CEN.14946)"},{"key":"bib34","series-title":"Neuroradiology","first-page":"1057","article-title":"Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly","volume":"58","author":"Shen","year":"2016","unstructured":"Shen M , Zhang QLiu WWang MZhu JMa ZHe WLi SShou XLi Y, et al.2016Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology581057\u20131065. (https:\/\/doi.org\/10.1007\/S00234-016-1728-4)"},{"key":"bib35","series-title":"Pituitary","first-page":"916","article-title":"Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German acrostudy cohort","volume":"18","author":"Sievers","year":"2015","unstructured":"Sievers CBaur DMSchwanke ABuchfelder MDroste MMann K & Stalla GK2015Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German acrostudy cohort. Pituitary18916\u2013923. (https:\/\/doi.org\/10.1007\/S11102-015-0673-2)"}],"updated-by":[{"DOI":"10.1530\/erc-24-0043e","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000}}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/31\/7\/ERC-24-0043.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/31\/7\/ERC-24-0043.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/31\/7\/ERC-24-0043.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:56:47Z","timestamp":1784555807000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/25838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":35,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0043","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]}}}